Lucy Day
Director of Finance/CFO chez AN2 THERAPEUTICS, INC.
Fortune : 99 538 $ au 31/03/2024
Profil
Lucy O.
Day is currently the Chief Financial & Accounting Officer at AN2 Therapeutics, Inc. She also holds the position of Chief Financial Officer at the same company since 2019.
Prior to her current roles, she worked as Vice President at Bank of America Corp.
from 1990 to 1994.
From 1994 to 2002, she served as the Chief Financial Officer at Centaur Pharmaceuticals, Inc. Following that, she held the position of CFO, VP-Human Resources & Finance at Anacor Pharmaceuticals LLC from 2002 to 2016.
Ms. Day completed her undergraduate degree at the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0,10% | 15/03/2024 | 30 627 ( 0,10% ) | 99 538 $ | 31/03/2024 |
Postes actifs de Lucy Day
| Sociétés | Poste | Début |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Director of Finance/CFO | 01/11/2019 |
Anciens postes connus de Lucy Day
| Sociétés | Poste | Fin |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Director of Finance/CFO | 01/08/2016 |
| Centaur Pharmaceuticals, Inc. | Director of Finance/CFO | 01/01/2002 |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | 01/01/1994 |
Formation de Lucy Day
| University of California, Berkeley | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| AN2 THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Centaur Pharmaceuticals, Inc. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
